Sector: Biological Products, (No Diagnostic Substances)
Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026
Revolution Medicines presented exploratory subgroup analyses from the Phase 3 RASolute 302 trial at ESMO 2026 as a late-breaking abstract (LBA82), showing RASONQUE (daraxonrasib) delivered a consistent overall survival benefit versus chemotherapy across all evaluated RAS genotype subgroups in previously treated metastatic pancreatic cancer. The previously reported primary analysis showed median overall survival of 13.2 months with RASONQUE versus 6.7 months with chemotherapy (HR 0.40). Subgroup hazard ratios ranged from 0.32 (G12V) to 0.61 (G12R), and the benefit held even in tumors with no identified RAS mutation (HR 0.43) and across all standard chemotherapy regimens. RASONQUE is already FDA-approved in the U.S. for previously treated metastatic PDAC; CHMP recently issued a positive opinion in Europe and other regulatory reviews are underway. The data reinforce the drug's potential as a new standard of care and support the broader RAS(ON) development program.
Revolution Medicines to Report Financial Results for Third Quarter 2026 After Market Close on November 4, 2026
Revolution Medicines will report third-quarter 2026 financial results on Wednesday, November 4, 2026, after market close. Senior management will host a webcast at 4:30 p.m. ET that day to discuss the results and provide a corporate update, with a replay available for at least 14 days.
Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment
Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer
Revolution Medicines has begun treating patients in RASolve 308, a global Phase 3 trial of zoldonrasib plus pembrolizumab and chemotherapy as first-line treatment for metastatic RAS G12D non-squamous NSCLC. The randomized, double-blind study uses progression-free survival as its primary endpoint, with overall survival, response rate, and duration of response among key secondary endpoints. RAS G12D occurs in roughly 4% of NSCLC cases with no approved targeted therapy, and initial combination data showed encouraging antitumor activity and a favorable safety profile -- a key registrational step for the RAS(ON) inhibitor franchise.
Revolution Medicines Stock Has Surged 124% This Year · Analyst Sees More Room to Grow
Revolution Medicines’ RASONQUE(™) (daraxonrasib) Receives Positive CHMP Opinion Recommending Marketing Authorization in European Union for Metastatic Pancreatic Cancer
Revolution Medicines' RASONQUE (daraxonrasib) received a positive CHMP opinion recommending EU marketing authorization for adults with metastatic pancreatic adenocarcinoma after at least one prior systemic therapy. The recommendation rests on the Phase 3 RASolute 302 trial, in which RASONQUE cut the risk of death by 60% versus chemotherapy (HR 0.40), with median overall survival of 13.2 months versus 6.7 months. If approved by the European Commission, RASONQUE would be the first broad RAS-targeted treatment option in the EU for metastatic pancreatic cancer, following its U.S. FDA approval on August 26, 2026.
RVMD: 8-K · debt financing
Revolution Medicines announced that the FDA approved RASONQUE (daraxonrasib) for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. The approval triggered funding of a $250.0 million Tranche A loan from Royalty Pharma on October 8, 2026, part of a $750.0 million senior secured facility. The loan bears interest at three-month Term SOFR (3.50% floor) plus 5.75%, is interest-only, and matures October 8, 2032; the company paid a $5.0 million draw fee. The company elected not to draw the associated $250.0 million Tranche 3 royalty payment, preserving $500.0 million of additional milestone-based loan availability and $500.0 million of additional royalty purchase price availability for future needs.
Revolution Medicines Begins Treating Patients in Phase 3 RASolute 309 Trial Evaluating RASONQUE™ (daraxonrasib) Plus Zoldonrasib as First-Line Treatment for Metastatic RAS G12D Pancreatic Cancer
Revolution Medicines has begun treating patients in RASolute 309 (NCT07805954), a global randomized Phase 3 trial testing RASONQUE plus zoldonrasib as a first-line treatment for metastatic RAS G12D pancreatic cancer. The open-label study compares the RAS(ON) inhibitor doublet against gemcitabine and nab-paclitaxel, with dual primary endpoints of progression-free and overall survival. It is the first Phase 3 study of a RAS(ON) inhibitor doublet approach. RASONQUE is already FDA-approved in previously treated metastatic PDAC, and the company cites approximately 55,000 U.S. PDAC diagnoses annually with a roughly 3% five-year survival rate in metastatic disease. Serious adverse reactions occurred in 30% of patients treated with RASONQUE in the approved setting, with warnings including GI perforation and ILD/pneumonitis.
Revolution Medicines (NASDAQ:RVMD) Stock: Insider Elizabeth Anderson Sells 10,143 Shares
Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?
Alan Sandler Sells 341 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Jack Anders Sells 4,053 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Stephen Michael Kelsey Sells 92,531 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?
Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for RASONQUE™ (daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer
The FDA granted Breakthrough Therapy Designation to RASONQUE (daraxonrasib) in combination with gemcitabine and nab-paclitaxel (GnP) chemotherapy for treatment-naive metastatic pancreatic adenocarcinoma, targeting use in the first-line setting. This is the third Breakthrough Therapy Designation for RASONQUE and the fifth across Revolution Medicines' RAS(ON) inhibitor portfolio. The designation rests on Phase 1/2 RMC-GI-102 data showing encouraging preliminary antitumor activity and a manageable safety profile in frontline RAS-mutant metastatic PDAC. The designation supports RASolute 303, the ongoing global Phase 3 trial testing RASONQUE as monotherapy and with GnP versus GnP alone in previously untreated metastatic PDAC — an expansion beyond the drug's recently FDA-approved second-line indication. The commercial stakes are large: approximately 55,000 people are diagnosed with PDAC in the U.S. each year, more than 50,000 die annually, and five-year relative survival in metastatic disease is roughly 3%.
Insider Selling: Revolution Medicines (NASDAQ:RVMD) Director Sells $3,585,823.80 in Stock
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?
Revolution Medicines Got Its Breakthrough-What Moves It Next?
Revolution Medicines (RVMD) Up 6.6% Since Last Earnings Report: Can It Continue?
New England Journal of Medicine Publishes Phase 1/2 Clinical Data on Revolution Medicines’ RASONQUE™ (daraxonrasib) in Metastatic Non-Small Cell Lung Cancer
The New England Journal of Medicine published Phase 1/2 data on Revolution Medicines' RASONQUE (daraxonrasib) in previously treated RAS mutant non-small cell lung cancer, based on 136 patients in the RMC-6236-001 trial with a July 21, 2025 data cutoff. In the 38 docetaxel-naive patients treated at 160 mg to 220 mg, the confirmed objective response rate was 42% and disease control rate was 89%, with median progression-free survival of 8.3 months and median overall survival of 16.0 months. Grade 3 treatment-related adverse events occurred in 25% of patients, with no Grade 4 or Grade 5 events at these dose levels. The data support the ongoing Phase 3 RASolve 301 trial comparing RASONQUE with docetaxel in previously treated RAS mutant NSCLC, and add validation on top of the drug's recent FDA approval in metastatic pancreatic cancer. RASONQUE remains investigational for NSCLC.
RVMD: 8-K · material agreement
Revolution Medicines agreed on August 27, 2026 to lease the entirety of four buildings at 1600, 1700, 1800 and 1900 Seaport Boulevard in Redwood City, California, comprising approximately 672,000 rentable square feet, to serve as its new headquarters. The deal is structured as four separate leases with affiliated landlords that are subsidiaries of Pacific Shores Phase II Associates, LLC. At full commencement, aggregate base rent begins at roughly $2.7 million per month and increases about 3% annually, with initial terms ending in September 2042 and three five-year extension options. The company receives approximately $23.1 million of base rent abatement through January 2030 plus about $115.9 million in tenant improvement allowances, with an election for up to $40.3 million more amortized at 10% annually. The leases take effect only if the landlords complete their Phase II property acquisition: the company can terminate if the closing has not occurred by December 31, 2026, and the leases automatically terminate if the closing has not occurred by April 29, 2027. The filing also discloses a related-party dimension: Farallon Capital Management, which reported beneficial ownership of approximately 6.4% of Revolution Medicines as of June 30, 2026, indirectly owns a majority interest in the landlords through managed funds. The full lease documents will be filed as exhibits to the company's Form 10-Q for the quarter ending September 30, 2026.
Revolution Medicines: Strong Buy RASONQUE FDA Approval And Zoldonrasib PDAC Expansions
Revolution Medicines: RASONQUE's FDA Approval Portends A New Oncology Titan
Revolution Medicines Wins FDA Approval for RASONQUE in Metastatic Pancreatic Cancer
Revolution Medicines Won FDA Approval One Month After Filing. Analysts See $11.5 Billion in Peak Sales.
Revolution Medicines, Inc. (RVMD) Discusses FDA Approval of RASONQUE for Metastatic Pancreatic Cancer and Implications for RAS-Driven Therapy Transcript
RVMD Secures FDA Win, Gets Nod for Rasonque in Pancreatic Cancer
When Revolution Medicines' FDA Win Lifts Other Boats: SELLAS Life Sciences Stock Surges
RVMD: 8-K · fda approval
Revolution Medicines announced that on August 26, 2026 the U.S. Food and Drug Administration approved RASONQUE (daraxonrasib) for adult patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy. The approval was based on RASolute 302, a global randomized Phase 3 trial that evaluated once-daily oral RASONQUE against investigator's choice of cytotoxic chemotherapy in previously treated metastatic pancreatic adenocarcinoma. RASONQUE tablets are now available in the United States for eligible patients, with a wholesale acquisition cost of $39,800 for a 30-day supply at the recommended daily dose, marking the company's transition to commercial-stage operations.
U.S. FDA Approves Revolution Medicines’ RASONQUE™ (daraxonrasib), the First Broad RAS-Targeted Medicine in Metastatic Pancreatic Cancer
Revolution Medicines received FDA approval for RASONQUE as the first broad RAS-targeted medicine for metastatic pancreatic adenocarcinoma. The approval is supported by Phase 3 data demonstrating a 60% reduction in the risk of death and a median overall survival of 13.2 months versus 6.7 months for chemotherapy. RASONQUE is available immediately in the U.S. as a once-daily oral tablet, supported by the launch of the company’s (ON)Path patient assistance program.
Revolution Medicines Wins FDA Approval for Pancreatic Cancer Pill. What It Means for the Stock.
The FDA approved a new drug from Revolution Medicines that promises to transform treatment of pancreatic cancers that kill many patients within a year of diagnosis
Revolution Medicines gets FDA nod for targeted pancreatic cancer drug
Billionaire Stanley Druckenmiller Continues to Load Up on Revolution Medicines. Does He Know Something Wall Street Doesn't?
Why Revolution Medicines May Be Big Pharma's Next Takeover Target
Revolution Medicines (NASDAQ:RVMD) Sets New 12-Month High – Should You Buy?
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
BeOne Medicines entered a strategic collaboration with Revolution Medicines to evaluate combinations of its own oncology assets with Revolution's four clinical-stage RAS(ON) inhibitors. Under a regional rights agreement, BeOne gained exclusive development and commercialization rights to these four Revolution assets in select Asian markets, while Revolution retains rights in other regions including Japan and South Korea. BeOne will fund and conduct a global registrational Phase 3 study for one of the RAS(ON) inhibitors as part of the arrangement.
High Risk, High Reward: Inside The Revolution Medicines Bull Case
RVMD Posts Wider-Than-Anticipated Loss in Q2, Lifts '26 Expense View
Revolution Medicines Q2 Earnings Call Highlights
Revolution Medicines, Inc. (RVMD) Q2 2026 Earnings Call Transcript
RVMD: 10-Q · periodic report
Revolution Medicines filed its Q2 2026 Form 10-Q reporting a net loss of $644.4 million, or $3.06 per share, more than double the $247.8 million loss a year earlier, bringing the six-month loss to $1.1 billion and the accumulated deficit to roughly $4.0 billion. The wider losses reflect R&D spending of $394.9 million (up from $224.1 million) across multiple Phase 3 programs, a $151.0 million non-cash charge from the change in fair value of its warrant liability, and G&A that jumped to $110.2 million as commercial infrastructure is built out. The balance sheet is well capitalized: about $3.9 billion in cash, equivalents and marketable securities after an April 2026 follow-on of 12.1 million shares at $142.00 raised $1.73 billion gross, $500 million of 0.50% convertible notes due 2033, and a $250 million Tranche 2 royalty payment from Royalty Pharma in May; management says existing capital funds operations for at least 12 months. On the pipeline, daraxonrasib's Phase 3 RASolute 302 trial showed median overall survival of 13.2 months versus 6.7 months for chemotherapy (hazard ratio 0.40, p<0.0001) in second-line pancreatic cancer, and the FDA has accepted the company's first NDA — keeping it on track for a potential first launch, though it still has no approved products or revenue.
Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines announced FDA acceptance of the NDA for daraxonrasib in pancreatic cancer and secured Breakthrough Therapy Designation in lung cancer, with an Expanded Access Program now serving over 2,000 patients. New data in first-line non-small cell lung cancer demonstrated high response rates, with the elironrasib combo showing an 85% ORR and the zoldonrasib combo showing 82% ORR, supporting planned Phase 3 trials. The company reported a net loss of $644.4 million for the quarter but holds a strengthened cash position of $3.9 billion following recent financings and raised full-year guidance to $2.1-$2.2 billion in operating expenses.
Revolution Medicines to Report Financial Results for Second Quarter 2026 After Market Close on August 5, 2026
Revolution Medicines announced it will report financial results for the second quarter of 2026 after the market closes on August 5, 2026. Management will host a webcast at 4:30 p.m. ET that day to discuss quarterly results and provide an update on corporate progress. A replay of the webcast will be archived and available on the company's website for at least 14 days.
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines announced that the FDA has accepted for review the New Drug Application for daraxonrasib for previously treated metastatic pancreatic ductal adenocarcinoma. The submission is supported by data from the Phase 3 RASolute 302 trial, which met all primary and key secondary endpoints, showing unprecedented improvements in overall survival and progression-free survival. Daraxonrasib has been granted Breakthrough Therapy and Orphan Drug designations by the FDA and is under phased review by the EMA, positioning it as a potential new standard of care.
This Stock Has Skyrocketed 125% in 2026 -- and Billionaire Stanley Druckenmiller Is Loading Up on It
Better Growth Buy: Axsome vs Revolution Medicines
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
The European Medicines Agency (EMA) has initiated a phased review of Revolution Medicines' lead asset daraxonrasib for pancreatic cancer, aiming to accelerate assessment ahead of a full marketing authorization application. This regulatory milestone follows positive results from the pivotal Phase 3 RASolute 302 trial, which showed unprecedented improvements in overall survival and progression-free survival compared to standard chemotherapy. Simultaneously, the company’s rolling New Drug Application (NDA) submission to the U.S. FDA under the Commissioner’s National Priority Voucher pilot program is nearing completion, signaling a coordinated global push for approval.
Revolution Medicines Is Up Nearly 140% in 2026. Is the Hot Biotech Stock Still a Buy?
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines presented Phase 1/2 data at ESMO GI for zoldonrasib combinations in RAS G12D metastatic pancreatic cancer, showing an 82% objective response rate with modified FOLFIRINOX and 61% with gemcitabine plus nab-paclitaxel in first-line patients. In previously treated patients, the combination of zoldonrasib and daraxonrasib demonstrated a 50% ORR in second-line and 47% in third-line-plus cohorts, with median progression-free survival of 9.6 months and 7.6 months respectively. These results support the company's dual Phase 3 strategy, comprising the ongoing RASolute 305 trial and the planned RASolute 309 trial in previously untreated metastatic RAS G12D pancreatic cancer.
Revolution Medicines Has a $40 Billion Market Cap and Generates No Revenue. Here's Why That's Not Absurd.
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines announced it will present data from its RAS(ON) inhibitor pipeline at the 2026 ESMO Gastrointestinal Cancers Congress in Munich. The program includes two oral presentations on Phase 1/2 trials evaluating zoldonrasib in combination regimens for metastatic pancreatic ductal adenocarcinoma. Two poster presentations will highlight Phase 3 trials-in-progress for daraxonrasib in both first-line metastatic and adjuvant pancreatic cancer settings.
RVMD Starts Treatment in Phase III Pancreatic Cancer Study on Zoldonrasib
Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
Revolution Medicines has initiated the pivotal Phase 3 RASolute 305 trial evaluating zoldonrasib plus chemotherapy in first-line metastatic RAS G12D pancreatic ductal adenocarcinoma. The trial targets a high-prevalence mutation found in roughly 40% of pancreatic cancer patients, a disease with a five-year survival rate of only 3%. This builds on recent positive second-line data for daraxonrasib, reinforcing the clinical validation of the company's RAS(ON) inhibition platform.
RVMD: 8-K · leadership change
Dr. Steve Kelsey, President of Research and Development, has announced his retirement effective January 4, 2027, following a transition to a senior advisor role starting July 1, 2026. The company intends to appoint Dr. Kelsey to its board of directors upon his retirement, pending board approval, to maintain continuity. At the annual meeting held on June 18, 2026, stockholders elected directors Alexis Borisy and Mark A. Goldsmith to Class III terms. Stockholders also ratified PricewaterhouseCoopers LLP as the company's independent auditor for the fiscal year ending December 31, 2026 and approved executive compensation on an advisory basis.
Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.
Revolution Medicines announced that Steve Kelsey, President of R&D, will transition to Senior Advisor to the CEO on July 1, 2026, and retire from employment in January 2027, at which point he is expected to join the Board of Directors. The company is implementing a new R&D leadership structure effective July 1, with Chief Development Officer Alan Sandler and Chief Scientific Officer Jan Smith overseeing their respective departments, while Xiaolin Wang assumes the new role of EVP of integrated portfolio strategy. Dr. Kelsey has led R&D since 2017 and was central to the discovery of the company's RAS(ON) inhibitor portfolio, which includes clinical candidates daraxonrasib and elironrasib.
Revolution Medicines: Strong Data, Big Market (Rating Upgrade)
Can Revolution Medicines Be a Game-Changer Stock?
Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?
Revolution Medicines Is Up 97% This Year: Here Are the Bull and Bear Cases for This Soaring Biotech Stock.
Platform Biotech Models Draw Investor Eyes as Drug-Delivery Markets Head Toward $410 Billion
BioMedWire published a paid editorial focusing primarily on Oncotelic Therapeutics (OTLC) and its drug-delivery platforms. CytoDyn (CYDY) is mentioned briefly as one of several companies developing scalable biotechnology platforms. The article notes that CytoDyn has enrolled the first participant in its Expanded Access Program for leronlimab in triple-negative breast cancer patients.
Revolution Medicines, Inc. (RVMD) Discusses Positive Clinical Results and Implications for Metastatic Pancreatic Cancer Treatment Transcript
RVMD Stock Rises on Detailed Results From Pancreatic Cancer Study
Revolution Medicines Jumps 12% As Cancer Drug Data Strengthens Case
Revolution Medicines' Pancreatic Cancer Pill Doubles Survival, Cuts Death Risk 60% in Trial As Stock Sits Near All-Time Highs
Revolution Medicines Announces ASCO Plenary Presentation Highlighting Unprecedented Results from Pivotal Phase 3 RASolute 302 Clinical Trial of Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines announced pivotal Phase 3 results for daraxonrasib in metastatic pancreatic cancer, showing a 60% reduction in the risk of death compared to standard chemotherapy. The trial met all primary and key secondary endpoints, with median overall survival of 13.2 months versus 6.7 months for chemo, and significantly improved progression-free survival and quality of life metrics. Results were published in The New England Journal of Medicine and presented as a plenary session at ASCO. The company intends to submit a New Drug Application to the FDA using a Commissioner’s National Priority Voucher.
Revolution Medicines to Host Investor Conference Call on Positive RASolute 302 Results Following 2026 ASCO Presentation
Revolution Medicines announced positive results from its Phase 3 RASolute 302 trial evaluating daraxonrasib in metastatic pancreatic cancer. The data was presented during the Plenary Session at the 2026 ASCO Annual Meeting, highlighting the significance of the findings. Senior management will host a webcast on May 31 at 7:00 pm ET to discuss the results in detail.
Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report
US cancer clinics scramble to get experimental Revolution Medicines pancreatic cancer drug
RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View
Revolution Medicines Announces Publication in New England Journal of Medicine of Phase 1/2 Clinical Data on Daraxonrasib in Pancreatic Cancer
Revolution Medicines announced that the New England Journal of Medicine published Phase 1/2 data for daraxonrasib in patients with metastatic RAS mutant pancreatic ductal adenocarcinoma (PDAC). The publication highlights findings that supported the initiation of the Phase 3 registrational trial RASolute 302, which recently reported topline results showing an unprecedented overall survival benefit versus standard chemotherapy. Daraxonrasib has received FDA Breakthrough Therapy and Orphan Drug designations and is currently being evaluated in four global Phase 3 trials across RAS-addicted cancers including pancreatic and non-small cell lung cancer.
Promising Revolution Medicines pancreatic cancer drug has high rate of mostly manageable side effects
Revolution Medicines Reports First Quarter 2026 Financial Results and Update on Corporate Progress
Revolution Medicines announced positive topline results from the Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer, showing a statistically significant improvement in overall survival (13.2 months vs 6.7 months) compared to chemotherapy. The company plans to submit these data to global regulatory authorities, including the FDA, and has initiated an Expanded Access Program for eligible patients. In April 2026, the company strengthened its financial position with $2.2 billion in gross proceeds from concurrent offerings of common stock and convertible notes, ending the quarter with $1.9 billion in cash and equivalents. For the first quarter, the company reported a net loss of $453.8 million, driven by increased R&D and G&A expenses, and updated its full-year 2026 GAAP operating expense guidance to $1.7 billion to $1.8 billion.
US FDA authorizes early access to Revolution's pancreatic cancer pill
Revolution Medicines to Report Financial Results for First Quarter 2026 After Market Close on May 6, 2026
Revolution Medicines announced it will report first quarter 2026 financial results after market close on Wednesday, May 6, 2026. Senior management will host a webcast at 4:30 p.m. ET that day to discuss the results and provide a corporate update. The company is a late-stage clinical oncology firm developing RAS(ON) inhibitors for RAS-addicted cancers.
There's a Revolution in Cancer. But Can Big Pharma Afford It?
RVMD: DEF 14A · proxy statement
Revolution Medicines has released its definitive proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 18, 2026, to be held virtually. The board recommends voting for the election of two Class III directors, Alexis Borisy and Mark A. Goldsmith, as well as the ratification of PricewaterhouseCoopers LLP as the independent auditor. The filing includes a non-binding advisory vote to approve executive compensation, noting that the CEO's total compensation was approximately $14.7 million in 2025. The proxy also details director compensation, committee structures, and corporate governance guidelines, indicating a standard uncontested annual meeting.
Revolution Medicines Has a Market Cap of $29 Billion and Generates No Revenue. Here's Why Its Valuation May Not Be as Ridiculous as It Seems
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
Revolution Medicines presented updated Phase 1/2 data for daraxonrasib in first-line metastatic pancreatic cancer, showing an objective response rate of 58% in combination with gemcitabine and nab-paclitaxel (GnP) and 47% as monotherapy. The safety profiles were described as manageable, with no Grade 5 treatment-related adverse events reported in the combination cohort and no Grade 4 or 5 events in the monotherapy cohort. These results support the continued evaluation of daraxonrasib in the ongoing Phase 3 RASolute 303 trial for previously untreated metastatic PDAC.
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting
Revolution Medicines announced preclinical data for RM-055, a novel class of mutant-targeted catalytic RAS(ON) inhibitors, at the AACR Annual Meeting. In xenograft models of pancreatic, lung, and colorectal cancers, RM-055 drove deep and durable tumor regressions and overcame resistance to prior RAS inhibition. The mechanism accelerates the conversion of active mutant RAS to an inactive state, potentially offering a wider therapeutic window by sparing wild-type RAS in normal tissues.
Revolution Medicines to Present Pivotal Phase 3 RASolute 302 Clinical Trial Results for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer During a Plenary Session at the 2026 ASCO Annual Meeting
Revolution Medicines announced that detailed results from the pivotal Phase 3 RASolute 302 trial of daraxonrasib in previously treated metastatic pancreatic cancer will be presented in a Plenary Session at the ASCO Annual Meeting. The topline results previously reported an unprecedented overall survival benefit, with statistically significant and clinically meaningful improvements in progression-free and overall survival compared to standard chemotherapy. Daraxonrasib, an oral RAS(ON) multi-selective inhibitor, has received FDA Breakthrough Therapy and Orphan Drug Designations for this indication and is being evaluated in four global Phase 3 trials.
Revolution Medicines to Present Updated Phase 1 Clinical Data for Zoldonrasib in Patients with Previously Treated KRAS G12D Non-Small Cell Lung Cancer at the 2026 AACR Annual Meeting
Mark Goldsmith Sells 120,000 Shares of Revolution Medicines (NASDAQ:RVMD) Stock
Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Revolution Medicines, Inc. Prices $2.0 Billion in Concurrent Upsized Offerings of Common Stock and Convertible Senior Notes
Revolution Medicines: 'Strong Buy' On Daraxonrasib Win And Expansions Underway
RVMD Stock Rallies 41% on Positive Phase III Pancreatic Cancer Data
